Mason, OH, United States
Mason, OH, United States
SEARCH FILTERS
Time filter
Source Type

Global Pharmacogenomics Market Information by Application (drug safety, Tailor treatments, drug discovery), By Therapeutic application (cancer, oncology, cardiovascular) By Methods (haplotype analysis, multivariate techniques) - Forecast to 2027Pune, India - April 25, 2017 /MarketersMedia/ — Market Highlights: Pharmacogenomics are popularly known as personalized medicines and are defined as Customized/ personalized medicines or customized medical treatment to the specific characteristics of each patient. This notion basically, comprises the ability to classify individuals into the groups or categories that are uniquely or excessively prone to a particular disease or responsive to a specific treatment. Emergence of new healthcare technologies and rapid advancement such as GenX sequencing, Digital Polymerase Chain Reaction (PCR) and High Throughput Screening (HTS), are the key driving factors for the global market of Pharmacogenomics. With the increasing demand for diagnostic tests leaded by the growing emphasize of patients on pre-diagnosis treatments, increasing genetic disorders & mutational diseases, and government initiatives and investment in research and development programs, the Diagnostic Test segment has out grown the other segments holding the largest market share. Key Players • Myriad Genetics, Inc (U.S) • Transgenomic, Inc(U.S) • 23andMe (U.S) • Pathway Genomics (CA) • Genetech (CA) • GeneDX (U.S) • Teva Pharmaceutical Industries Ltd.(Israel) • Illumina, Inc.(U.s) • Assurex Health, Inc.(U.s) Request a Copy of Sample Report @ https://www.marketresearchfuture.com/sample_request/1177 Global Pharmacogenomics Market’s Current trends are prompting the service provider segments to collaborate and entering into partnerships with healthcare providers, academic institutions, pharmaceuticals and biotechnology companies to support the growth of the Pharmacogenomics market and thus, service segment is anticipated to grow at a high CAGR from 2016 to 2027 Furthermore, the Pharmaceutical segment will also gain from traction of the patients due to increasing awareness about the benefits of Pharmacogenomics solutions and adoption of these solutions in developing regions. The report for Pharmacogenomics of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. Segments The market for pharmacogenomics is segmented into mainly three; by application, by therapeutic application, by end user and its various sub-segments. By application include drug safety, Tailor treatments, drug discovery and others. Whereas by therapeutic application include cancer, oncology, cardiovascular and others. Furthermore by methods include haplotype analysis, multivariate techniques, quantitative trait analysis and others. Taste the market data and market information presented through more than 50 market data tables and figures spread in 120 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global Pharmacogenomics Market Research Report - Forecast to 2027” Access Report Details @ https://www.marketresearchfuture.com/reports/pharmacogenomics-market Study Objectives of Pharmacogenomics • To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the global pharmacogenomics market • To provide insights about factors affecting the market growth • To Analyze the Pharmacogenomics Market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia, and Middle East & Africa. • To provide country level analysis of the market with respect to the current market size and future prospective • To provide country level analysis of the market for segment by application, by therapeutic application, by methods and its sub-segments. • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global pharmacogenomics market. Make an Enquiry @ https://www.marketresearchfuture.com/enquiry/1177 Americas • North America • US • Canada • Latin America Europe • Western Europe • Germany • France • Italy • Spain • UK • Rest of Western Europe • Eastern Europe Asia– Pacific Asia • China • India • Japan • South Korea • Rest of Asia Pacific The Middle East& Africa The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions. Browse Related Reports:- Global Infusion Systems market, by Product Type (Ambulatory Pumps, I.V. Disposables, Syringe Pump Systems, Volumetric Pump Sets and others), by applications (chemotherapy, cardiovascular diseases, Diabetes, Pediatrics and others) by end users (Hospitals, Clinics, Research Laboratories and others) - Forecast to 2027 https://www.marketresearchfuture.com/reports/infusion-systems-market About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. Contact Info:Name: Akash AnandEmail: akash.anand@marketresearchfuture.comOrganization: Market Research FutureAddress: Hadapsar Pune, India - 411028Phone: +1 646 845 9312Source URL: http://marketersmedia.com/pharmacogenomics-market-analysis-by-global-industry-growth-regions-types-and-forecasts-2027/190043For more information, please visit https://www.marketresearchfuture.com/reports/pharmacogenomics-marketSource: MarketersMediaRelease ID: 190043


News Article | December 19, 2016
Site: www.businesswire.com

CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Comprehensive Health Services, one of the nation’s largest and most experienced workforce medical services providers, has hired Patrick Hogenbirk as senior vice president and chief compliance officer. This position reports to President and CEO Gary Palmer, with additional reporting responsibilities to the company’s board of directors. Hogenbirk has more than 20 years of experience in corporate ethics and compliance. Most recently, Hogenbirk served as vice president and chief compliance officer with Assurex Health, a personalized medicine company, specializing in DNA-based drug treatment. He has held similar positions at Johnson & Johnson and Cardinal Health, where he was instrumental in establishing new ethics and compliance programs. “Comprehensive Health Services continues to grow, and with this growth comes increased operational complexities, requiring company-wide oversight,” said President and CEO Gary Palmer. “This position is in response to our expanding needs. We are committed to maintaining the highest ethical standards and full compliance on every contract and throughout our operations, functions, and processes, and the addition of Patrick to our senior leadership team reinforces our strong commitment and dedication.” Hogenbirk holds a Certified Compliance and Ethics Professional certificate from the Society of Corporate Compliance, and an Ethics and Healthcare Compliance Law certificate from Seton Hall University Law School and is a graduate of the University of Maryland and Park University. Hogenbirk is a veteran of the U.S. Air Force and retired as a Chief of Fire Protection for the 4th Air Force with more than 25 years of service. Founded in 1975, Comprehensive Health Services is one of the nation’s largest and most experienced providers of workforce medical services. We partner with Fortune 1000 companies and the U.S. government to solve the highly complex, large-scale health care challenges they face by implementing and managing cost-effective, customized medical programs for large and dispersed workforces. Our technology-driven, flexible health care solutions are capable of providing tailored services to ensure employers can meet the medical needs and compliance issues of their employees anywhere in the world. For more information, please visit www.chsmedical.com. For news and updates, follow us on Twitter @CHSMedical, LinkedIn, or like us on Facebook.


News Article | June 20, 2017
Site: www.prnewswire.com

Assurex Health initially selected the MassARRAY System for its laboratory-developed test because it provides a robust, simple, highly cost-effective workflow resulting in faster time-to-result and greater capacity for the laboratory. To date, Assurex Health has run over 150,000 GeneSight tests using the MassARRAY System.  Going forward under the new partnership, Assurex Health expects to significantly increase the number of GeneSight test samples run on the platform. "Agena Bioscience is passionate about providing affordable multiplex molecular systems to laboratories worldwide to help them significantly expand access to clinically relevant genomic data.  Pharmacogenomics testing is a foundational application in the sweet spot for targeted genetic analysis on our MassARRAY System. We are proud to be chosen by Assurex Health, and see the partnership as a significant accelerator into this clinical market segment," said Pete Dansky, Chief Executive Officer at Agena Bioscience. The MassARRAY System enables high-throughput, accurate detection of SNPs, INDELs, and copy number variations across a variety of genetic applications. The flexibility and scalability of the platform facilitates easy development of custom panels and validation across large numbers of samples. Assurex Health Vice President, Laboratory Operations, Sandra Gunselman, Ph.D. commented, "The GeneSight test has seen tremendous adoption and growth, with hundreds of thousands of patients tested. We are committed to providing our customers with rapid turnaround time and scalability that enables us to meet the ever-growing demand for the test. With fewer touch points and less variability in workflow, our team can continue to accelerate service to psychiatrists and their patients." The GeneSight Psychotropic test is supported by five published clinical studies demonstrating its efficacy and cost effectiveness.  For more information visit www.genesight.com. Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY® System. The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis, and is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research.  For more information about Agena, visit www.agenabio.com. Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc., is an informatics-based, personalized medicine company providing treatment decision support to healthcare providers for behavioral health and chronic pain conditions. Assurex helps people achieve mental wellness with advanced CPGx®, a proprietary combinatorial pharmacogenomics technology that provides individualized treatment support for neuropsychiatric conditions.   Assurex Health is the only company in the category with multiple peer-reviewed, published studies that demonstrate the clinical validity and clinical utility of the GeneSight® test, including its substantial healthcare cost savings benefit. The Company has grown every quarter and has expanded internationally through a partnership with Canada's Centre for Addiction and Mental Health (CAMH). For more on how Assurex Health is helping people gain mental wellness, visit www.AssurexHealth.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/agena-bioscience-announces-expanded-partnership-with-assurex-health-300475523.html


News Article | May 10, 2017
Site: www.prweb.com

Verge Genomics (https://www.vergegenomics.com/), a leading drug discovery company utilizing genomic data for neuroscience therapeutics, announced today that C. Anthony (Tony) Altar, Ph.D., has joined the company as Chief Scientific Officer. Dr. Altar has over 35 years of experience leading teams harnessing genomic data to discover and develop first-in-class medicines for the central nervous system. As the former Global Head of Neuroscience at Otsuka, he led the team that discovered aripiprazole (Abilify™), which was first approved by the FDA in 2002 and is now one of the highest grossing drugs for psychiatric diseases on market. Most recently, as Chief Scientific Officer of Assurex Health, he created pharmacogenomic products for ADHD and pain, whose commercial successes yielded an acquisition by Myriad Genetics in 2016. Dr. Altar also served as CSO of Psychiatric Genomics and held various scientific leadership positions at Regeneron and Genentech. Dr. Altar completed his postdoctoral training in Psychobiology at UC Irvine and holds a Ph.D. in Psychology from UC Santa Barbara. “Tony has an unparalleled track record for driving forward the life cycle of medicine from inception to commercial success, which has immensely benefited numerous patients suffering from CNS-related diseases,” said Alice Zhang, Chief Executive Officer of Verge Genomics. “We are very excited to have him on board to help pioneer the next phase of Verge’s growth.” Verge is a next-generation drug discovery company that is using human genomic data to accelerate the discovery of treatments for neurodegeneration. Founded by scientists from leading neuro-genomics labs, the Verge team is 12 people including 10 Ph.D.’s in machine learning, neuroscience, applied math, biophysics, statistics, and computational biology from UCLA, Stanford, Oxford, and UCSF, two former professors, and two pharma veterans.


Globally the market for pharmacogenomics is increasing rapidly mainly due to increasing safety in drug. The factors that influence the growth of Pharmacogenomics market; rising utilization in medication revelation processes, increasing interest for customized drugs, expanding security in treatment, Improve evidence of guideline for adequacy trials. • Myriad Genetics, Inc (U.S) • Transgenomic, Inc(U.S) • 23andMe (U.S) • Pathway Genomics (CA) • Genetech (CA) • GeneDX (U.S) • Teva Pharmaceutical Industries Ltd.(Israel) • Illumina, Inc.(U.s) • Assurex Health, Inc.(U.s) The report for Pharmacogenomics of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The market for pharmacogenomics is segmented into mainly three; by application, by therapeutic application, by end user and its various sub-segments. By application include drug safety, Tailor treatments, drug discovery and others. Whereas by therapeutic application include cancer, oncology, cardiovascular and others. Furthermore by methods include haplotype analysis, multivariate techniques, quantitative trait analysis and others. Taste the market data and market information presented through more than 50 market data tables and figures spread in 120 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global Pharmacogenomics Market Research Report - Forecast to 2027” • To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the global pharmacogenomics market • To provide insights about factors affecting the market growth • To Analyze the Pharmacogenomics Market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia, and Middle East & Africa. • To provide country level analysis of the market with respect to the current market size and future prospective • To provide country level analysis of the market for segment by application, by therapeutic application, by methods and its sub-segments. • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global pharmacogenomics market. Americas • North America • US • Canada • Latin America Europe • Western Europe • Germany • France • Italy • Spain • UK • Rest of Western Europe • Eastern Europe Asia– Pacific Asia • China • India • Japan • South Korea • Rest of Asia Pacific The Middle East& Africa The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions. Global Infusion Systems market, by Product Type (Ambulatory Pumps, I.V. Disposables, Syringe Pump Systems, Volumetric Pump Sets and others), by applications (chemotherapy, cardiovascular diseases, Diabetes, Pediatrics and others) by end users (Hospitals, Clinics, Research Laboratories and others) - Forecast to 2027 https://www.marketresearchfuture.com/reports/infusion-systems-market At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. For more information, please visit https://www.marketresearchfuture.com/reports/pharmacogenomics-market


SALT LAKE CITY, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will present two new studies at the American Society of Dermatopathology (ASDP) annual meeting being held Oct. 27-30, 2016 in Chicago, Ill.  The research being presented validates the accuracy of Myriad myPath® Melanoma in differentiating benign skin nevi from malignant melanoma. “We are presenting landmark data from the largest outcomes-based study ever performed with a melanoma diagnostic,” said Loren Clarke, M.D., medical director, Dermatology, Myriad Genetic Laboratories.  “The myPath Melanoma test performed very well and identified patients with melanoma versus benign skin lesions with greater than 95 percent diagnostic accuracy, which is exceptional in molecular diagnostics for cancer, particularly given the extreme heterogeneity of melanoma.” “Pigmented or suspect skin lesions are difficult to diagnose in approximately 15 percent of cases,” said Sancy Leachman, M.D., Ph.D., chair of the Department of Dermatology in the Oregon Health & Science University School of Medicine and director of the Melanoma Research Program at the Knight Cancer Institute.  “A highly accurate biomarker like the myPath Melanoma test should help dermatologists augment their diagnosis of melanoma, improve patient care and lower healthcare costs.” Below are the featured presentations at ASDP (#ASDP2016). Poster Presentation Title: Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcome​. Presenter: Jennifer Ko. Date: Friday, Oct. 28, 2016: 4:15 – 5:00 p.m. and Saturday, Oct. 29, 2016 10:00 – 10:45 a.m. CT. In this study, research collaborators from the Cleveland Clinic, Stanford University and Nottingham University assessed the clinical accuracy (sensitivity and specificity) of the myPath Melanoma test against clinical outcomes in 182 patients with skin lesions (99 melanomas and 83 nevi) with more than 5 years of follow up.  The results show that the myPath Melanoma test accurately differentiated benign lesions from melanoma with a sensitivity of 93.8 percent and a specificity of 96.2 percent when compared to known clinical outcomes.   The diagnostic accuracy of the myPath Melanoma test was high even in a subset of difficult-to-diagnose cases and, in combination with two previous validation studies, the findings support its use as an adjunct method for the early and accurate diagnosis of melanoma. Podium Presentation Title: Gene Expression Signature as an Ancillary Method in the Diagnosis of Desmoplastic Melanoma​. Presenter: Loren Clarke. Date: Sunday, Oct. 30, 2016: 8:20 – 8:30 a.m. CT. The objective of this study was to assess the accuracy of the myPath Melanoma test in the differentiation of desmoplastic melanoma (DM) from benign skin lesions.  These lesions represent approximately one percent of melanomas, but are known to be very difficult to diagnose.  The analysis included samples from 20 patients with DM and 27 from patients with benign moles (nevi).  The results showed that the myPath Melanoma test was positive in 15 of the 20 known melanomas, negative in four and indeterminate in one.  The myPath score was negative in 24 of the benign nevi and indeterminate in three.  Based on these findings, the myPath Melanoma test demonstrated approximately 80 percent diagnostic accuracy in this very difficult-to-diagnose subtype. For more information about the meeting, please visit the ASDP website at https://www.asdp.org/annual-meeting/home/.  Follow Myriad on Twitter via @MyriadGenetics to stay informed about news and updates from the Company. About Melanoma Melanoma is one of the fastest growing cancers in the United States and can strike people of all ages, races and skin types. With a one-in-50 lifetime risk of developing melanoma, nearly 76,000 Americans are expected to be diagnosed with Stage I-IV melanoma and another 68,000 will be diagnosed with melanoma in situ – totaling approximately 144,000 total diagnoses.  Early and accurate diagnosis of melanoma is critical for long-term survival.  For more information visit: www.mypathmelanoma.com/ and www.myriadpro.com/melanoma. About Myriad myPath® Melanoma Myriad myPath Melanoma is a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. The test measures the expression of 23 genes and accurately distinguishes melanoma from benign nevi. About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, EndoPredict, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prolaris and GeneSight are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company presenting two new studies at the American Society of Dermatopathology Annual Meeting being held Oct. 27-30, 2016 in Chicago, Ill.; the accuracy and effectiveness of Myriad myPath Melanoma testing in differentiating benign skin nevi from malignant melanoma; and the Company’s strategic directives under the captions “About Myriad myPath Melanoma” and “About Myriad Genetics.” These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to changes in the governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of a healthcare clinic in Germany and Sividon Diagnostic and our planned acquisition of Assurex Health; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.


SALT LAKE CITY, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of the GeneSight® Psychotropic test to deliver medication cost savings for mental health disorders was published in the journal Clinical Therapeutics.[1]  GeneSight Psychotropic is a precision medicine genetic test that helps guide medication selection in patients with major depressive disorder (MDD) and is the foundation of the Company’s industry-leading portfolio of tests for neuroscience disorders. The study, entitled: "Economic utility: Combinatorial Pharmacogenomics and Medication Cost Savings for Mental Healthcare in a Primary Care Setting" is a subanalysis from a previous prospective study analyzing cost savings for patients receiving combinatorial pharmacogenomic testing.[2]  The current study compared savings among various types of health care providers (HCPs) and analysed the cost of treatment decisions that were congruent with GeneSight test results (i.e., medication decisions in concordance with the patients’ test results) with those that were incongruent.  Using pharmacy claims data from 2,168 patients with MDD, the new analysis compared medication costs six months prior to GeneSight testing and for one year post-testing. The analysis measured both treatment congruence and cost savings per patient based on the type of healthcare provider administering care.  The findings showed that primary care providers (PCPs) treat the majority of mental health patients receiving psychotropic medication prescriptions, including treatment resistant patients.  In fact, patients treated by PCPs had tried a median of five medications, similar to psychiatrists whose patients had tried six medications. The data also demonstrated that PCPs who treated patients congruently with the GeneSight test saved payers and patients an average of $3,998 compared to incongruent decisions (p<0.001).  Additionally, psychiatrists who treated patients congruently with the GeneSight test saved an average of $1,308. [1] Brown L., Lorenz R., Li J., et al, Economic utility:  Combinatorial pharmacogenomics and medication cost savings for mental healthcare in a primary care setting.  Clin Ther. 2017; Accessed online at: http://dx.doi.org/10.1016/j.clinthera.2017.01.022. [2] J.G. Winner, J.M. Carhart, C.A. Altar, et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res Opin, 31 (2015), pp. 1633–1643. "In the treatment of major depression, clinicians and payers are looking for sensible options to improve patient care, while lowering overall costs to healthcare systems," said Bryan M. Dechairo, Ph.D., chief medical and science officer, Assurex Health. "Prior studies demonstrated that the GeneSight test can be used to guide patient treatment decisions. Now, we know that GeneSight can lower costs across healthcare provider types, but was especially effective in generating cost savings among primary care physicians, which is important because they treat the majority of patients with mental illness.” Follow Myriad on Twitter via @MyriadGenetics to stay informed about news and updates from the Company. About The GeneSight® Test The GeneSight test helps healthcare providers make better treatment decisions based on a person’s genetic makeup. GeneSight testing is based on advanced CPGx® technology, a patented approach that analyzes variations and combinations of a person’s genes along with FDA-approved medications for behavioral health conditions and chronic pain.  Numerous peer-reviewed, published studies have proven its clinical benefits and substantial healthcare cost savings. More than 18,000 healthcare professionals have used GeneSight to improve healthcare for more than 450,000 patients. Learn more at www.GeneSight.com. About Assurex Health Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc., is an informatics-based, personalized medicine company providing treatment decision support to healthcare providers for behavioral health and chronic pain conditions. Assurex Health is the only company in the category with multiple peer-reviewed, published studies that demonstrate the clinical validity and clinical utility of the GeneSight test, including its substantial healthcare cost savings benefit. The Company has grown every quarter and has expanded internationally through a partnership with Canada’s Centre for Addiction and Mental Health (CAMH). For more on how Assurex Health is helping people gain mental wellness, visit www.AssurexHealth.com. About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the ability of the GeneSight Psychotropic test to drive medication cost savings for mental health disorders; the ability of the GeneSight test to guide medication selection in patients with major depressive disorder (MDD); GeneSight test being the foundation of the Company’s industry-leading portfolio of tests for neuroscience disorders; and the Company’s strategic directives under the caption “About Myriad Genetics.”  These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.


SALT LAKE CITY, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that a poster featuring the GeneSight® test will be presented at the Neuroscience Education Institute (NEI) Psychopharmacology Congress being held Nov. 3-6, 2016 in Colorado Springs, Colo. In this subanalysis of a previously published study, patients with generalized anxiety disorder (GAD) experienced significant cost savings when decisions congruent with the GeneSight report were made by healthcare providers.  In the previously published study, congruency with the GeneSight test was shown to deliver significant cost savings for patients with major depressive disorder (MDD). “We believe that GeneSight has the potential to improve outcomes for patients being treated with psychotropic drugs and eliminate a significant amount of waste in our healthcare system,” said Bryan M. Dechairo, Ph.D., chief medical and science officer, Assurex Health. “We look forward to sharing these data with the medical community and payers.” Below is a summary of the featured presentation at NEI (#NEI2016). Poster Presentation Title: GeneSight Psychotropic Decreases Medication Costs for Patients with Anxiety and Bipolar Disorders in a Large, Prospective Case-Control Project Presenter: Kim Horn. Date: Friday, Nov. 4, 2016: 6:00-7:30 p.m. MT. This study assessed the economic utility of the GeneSight test for 318 patients with generalized anxiety disorder (GAD) when healthcare providers made decisions congruent with the GeneSight test report. Patients in the GeneSight-guided group of the previously published study were subdivided into two groups. The first group included patients whose healthcare provider made treatment decisions congruent with the GeneSight test report. The second group included patients whose provider made treatment decisions incongruent with the test report. The analysis compared total medication costs between the congruent and incongruent groups for patients based on their diagnosis of GAD. The results showed that, for GAD patients, the savings for congruent versus incongruent decisions was $6,747 per member per year ($5736 vs $12,483, p<0.004). Importantly, GAD patients experienced greater savings in CNS medications (2-fold), antineoplastic medications (2.5-fold) and gastroenterology medications (2.8-fold). Patients with comorbid GAD and MDD whose medication regimens were congruent with the GeneSight test had the highest cost savings of any group ($10,573). This subanalysis showed significant cost savings for GAD patients when healthcare providers made decisions congruent with the GeneSight test report. Much of the cost savings came from classes of medicines used in primary care. Anxiety disorders are commonly seen in the primary care setting and are often associated with comorbid medical illnesses, such as heart disease, migraine headaches and back pain for which patients with anxiety often seek help from their primary care provider. The GeneSight test may have enabled healthcare providers to more appropriately treat the underlying anxiety disorder, thereby reducing the number of physical complaints that previously required medication. Additionally, the previously published study showed that patients whose treatment was guided by the GeneSight test experienced increased adherence and reduced polypharmacy, which may have also contributed to cost savings associated with primary care medications. About The GeneSight® Test GeneSight testing helps healthcare providers make better treatment decisions based on a person's genetic makeup. GeneSight testing is based on advanced CPGx® technology, a patented approach that analyzes variations and combinations of a person's genes along with FDA-approved medications for behavioral health conditions and chronic pain. Peer-reviewed, published studies have proven its clinical benefits and substantial healthcare cost savings. More than 15,000 healthcare professionals have used GeneSight with over 400,000 patients. Learn more at www.GeneSight.com. About Assurex Health Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc., is an informatics-based, personalized medicine company providing treatment decision support to healthcare providers for behavioral health and chronic pain conditions. Assurex helps people achieve mental wellness with advanced CPGx®, a proprietary combinatorial pharmacogenomics technology that provides individualized treatment support for neuropsychiatric conditions. Assurex Health is the only company in the category with multiple peer-reviewed, published studies that demonstrate the clinical validity and clinical utility of the GeneSight® test, including its substantial healthcare cost savings benefit. The Company has grown every quarter and has expanded internationally through a partnership with Canada's Centre for Addiction and Mental Health (CAMH). For more on how Assurex Health is helping people gain mental wellness, visit www.AssurexHealth.com. About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, EndoPredict, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prolaris and GeneSight are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company presenting a new study at the Neuroscience Education Institute Annual Meeting being held Nov. 3-6, 2016 in Colorado Springs, Colo.; the accuracy and effectiveness of the GeneSight test in selecting psychotropic drug therapy or saving the healthcare system money; and the Company’s strategic directives under the captions “About GeneSight” and “About Myriad Genetics.”  These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.


News Article | November 11, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “Medical Equipment Monthly Deals Analysis: August 2016 - M&A and Investment Trends” new report to its research database. The report spread across 84 pages with table and figures in it. Medical Equipment Monthly Deals Analysis: August 2016 - M&A and Investment Trends? report is an essential source of data and trend analysis on the mergers and acquisitions (M&As) and financings in the medical equipment industry. The report provides detailed information on M&As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the medical equipment industry in August 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, segments and geographies. Additionally, the report provides information on the top financial advisory firms in the medical equipment industry. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/medical-equipment-monthly-deals-analysis-august-2016-ma-and-investment-trends/ 2.3.4 Myriad Genetics to Acquire Assurex Health for up to USD410 Million 14 4.1.1 In Vitro Diagnostics - Deals of the Month 28 4.2.1 Healthcare IT - Deals of the Month 31 Scope - Analyze market trends for the medical equipment/medical devices market in the global arena - Review of deal trends in anesthesia and respiratory devices, cardiovascular devices, dental devices, diabetes care devices, diagnostic imaging, drug delivery devices, endoscopy devices, ENT devices, healthcare IT, hospital supplies, in vitro diagnostics, nephrology and urology devices, neurology devices, opthalmic devices, patient monitoring, surgical equipment, and wound care management segments - Analysis of M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships in the medical equipment market - Summary of medical equipment deals globally in the last six months - Information on the top deals that took place in the medical equipment market - Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa - League Tables of financial advisors in M&A and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs - Review the financial metrics, such as operating profit ratio, P/E ratio, and EV/EBITDA on mergers and acquisitions Reasons to buy - Enhance your decision making capability in a more rapid and time sensitive manner. - Find out the major deal performing segments for investments in your industry. - Evaluate the types of company divesting and acquiring assets and ways to raise capital in the market. - Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the medical equipment industry. - Identify growth segments and opportunities in each region within the industry. - Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc. announces that on August 11, 2015, the Board of Directors of Meridian Bioscience, Inc. elected two new independent directors, Catherine A. Sazdanoff and John C. McIlwraith, effective August 14, 2015. Ms. Sazdanoff is the CEO and President of Sazdanoff Consulting LLC, specializing in business development, management and strategy consulting. In addition, she is Strategic Advisor to mProve Health LLC, a mobile health technology company located in Arlington, Virginia. From 2006 to 2015, Ms. Sazdanoff held a number of executive positions with Takeda Pharmaceutical International, Inc. including Vice President, Head of Corporate Projects, VP, Global Business Development and VP, Corporate Development. Prior to her time at Takeda, Ms. Sazdanoff spent 22 years with Abbott Laboratories, where she held numerous executive positions. Ms. Sazdanoff received a B.A. from the University of Notre Dame and a J.D. from Northwestern University School of Law. Mr. McIlwraith co-founded Allos Ventures, a venture capital firm, in March 2010 and has served as a Managing Director there since that time. Prior to founding Allos Ventures, Mr. McIlwraith was a Managing Director of Blue Chip Venture Company, a Cincinnati-based venture capital and private equity firm, which he joined in 1997. He has served on the board of directors of more than 20 healthcare or information technology companies, and is currently the lead director of Assurex Health, Inc., an informatics-based precision medicine company providing treatment decision support to health care providers for behavioral health conditions. Prior to 1997, Mr. McIlwraith served as Senior Vice President of Strategic Planning and General Counsel of publicly-traded Quantum Health Resources, Inc., and was a partner in the Jones Day law firm. Mr. McIlwraith received a B.A. from Hillsdale College and a J.D. from Case Western Reserve University. John A. Kraeutler, Chairman and Chief Executive Officer, commented, “With the election of Catherine and John to the Board of Directors of Meridian Bioscience we have added key strategic and operating strengths to help guide our future growth. Our Nominating Committee has been working diligently for more than a year to add specific skills to the Board. During that period, we have met and interviewed many talented individuals and we are very pleased that Catherine and John have agreed to join our team. I look forward to working closely with both Catherine and John, along with our existing directors, as we build a strong future for Meridian Bioscience.” Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

Loading Assurex Health collaborators
Loading Assurex Health collaborators